An exploration of psychological symptoms in vasoactive hormone-secreting neuroendocrine tumours (carcinoid syndrome)

2016 ◽  
Author(s):  
Elizabeth Friend
Keyword(s):  
Carcinoid Syndrome ◽  
Neuroendocrine Tumours ◽  
Psychological Symptoms

Prevalence of non-carcinoid syndrome (non-CS) diarrhoea in patients with neuroendocrine tumours (NETs): a systematic literature review (SLR)

2019 ◽  
Author(s):  
Mohid S Khan ◽  
Thomas Walter ◽  
Amy Buchanan-Hughes ◽  
Lucie Keeber ◽  
Marion Feuilly ◽  
...  
Keyword(s):  
Literature Review ◽  
Systematic Literature Review ◽  
Carcinoid Syndrome ◽  
Neuroendocrine Tumours

scholarly journals Carcinoid syndrome caused by a serotonin-secreting pituitary tumour

2014 ◽  
Vol 170 (2) ◽  
pp. K5-K9 ◽  
Author(s):  
Louise A Lynggård ◽  
Eigil Husted Nielsen ◽  
Peter Laurberg
Keyword(s):  
Chromogranin A ◽  
Carcinoid Syndrome ◽  
Neuroendocrine Tumours ◽  
Somatostatin Receptor ◽  
Pituitary Tumour ◽  
Symptomatic Improvement ◽  
Single Positive ◽  
Primary Location ◽  
Pre Treatment ◽  
Positive Focus

BackgroundNeuroendocrine tumours are most frequently located in the gastrointestinal organ system or in the lungs, but they may occasionally be found in other organs.CaseWe describe a 56-year-old woman suffering from a carcinoid syndrome caused by a large serotonin-secreting pituitary tumour. She had suffered for years from episodes of palpitations, dyspnoea and flushing. Cardiac disease had been suspected, which delayed the diagnosis, until blood tests revealed elevated serotonin and chromogranin A in plasma. The somatostatin receptor (SSR) scintigraphy showed a single-positive focus in the region of the pituitary gland and MRI showed a corresponding intra- and suprasellar heterogeneous mass. After pre-treatment with octreotide leading to symptomatic improvement, the patient underwent trans-cranial surgery with removal of the tumour. This led to a clinical improvement and to a normalisation of SSR scintigraphy, as well as serotonin and chromogranin A levels.ConclusionTo our knowledge, this is the first reported case of a serotonin-secreting tumour with a primary location in the pituitary.

Treatment of metastatic midgut neuroendocrine tumour associated with carcinoid syndrome

2014 ◽  
Vol 155 (5) ◽  
pp. 194-198
Author(s):  
Andrea Uhlyarik ◽  
Erika Lahm ◽  
József Vachaja ◽  
Zsuzsanna Pápai
Keyword(s):  
Metastatic Disease ◽  
Case History ◽  
Carcinoid Syndrome ◽  
Neuroendocrine Tumours ◽  
Neuroendocrine Tumour ◽  
Somatostatin Receptor ◽  
Tumour Response ◽  
Tumour Resection ◽  
Peptide Receptor ◽  
Long Acting

Although the incidence of neuroendocrine tumours is low, their prevalence is high due to the usually slow course of the disease. Between July 1, 2008 and July 1, 2013 the authors evaluated 56 patients with well-differentiated or moderately differentiated neuroendocrine tumours; 36 patients with metastatic disease underwent treatment while 17 patients who had tumour resection were followed without additional treatment. All patients with metastatic disease received long acting octreotide, and additional therapy was based on the site of origin, grade of differentiation, Ki67 index, and focal labelling of the tumours during somatostatin-receptor or metaiodo-benzyl-guanidine scintigraphy. The authors present a detailed case history of a patient with carcinoid syndrome due to a metastatic midgut neuroendocrine tumour, who received long acting octreotide and peptide receptor radionuclide treatment. In this patient an objective tumour response was reached in addition to the resolution of symptoms of carcinoid syndrome. The authors conclude that the case history confirms previous observations showing that long acting octreotide combined with peptide receptor radionuclide treatment may provide long survival with good quality of life in a patient with metastatic midgut neuroendocrine tumour accompanied with carcinoid syndrome. Orv. Hetil., 2014, 155(5), 194–198.

scholarly journals Use of healthcare REsources and associated COsts in controlled versus uncontrolled carcinoid SYndrome in patients with neuroendocrine tumours: the RECOSY study

2021 ◽  
Author(s):  
A. Custodio ◽  
P. Jimenez-Fonseca ◽  
A. Carmona-Bayonas ◽  
M. J. Gomez ◽  
M. I. Del Olmo-García ◽  
...  
Keyword(s):  
Resource Use ◽  
Carcinoid Syndrome ◽  
Neuroendocrine Tumours ◽  
Healthcare Resource ◽  
General Health Questionnaire ◽  
Work Productivity ◽  
Healthcare Resource Use ◽  
University Hospitals ◽  
Activity Impairment ◽  
Cross Sectional

Abstract Purpose To report healthcare resource use and associated costs in controlled versus uncontrolled carcinoid syndrome (CS) in patients with neuroendocrine tumours. Methods A cross-sectional, non-interventional multicentre study was conducted with retrospective data analysis. Resource use was compared between two patient groups: those with controlled CS (> 12 months with no uncontrolled CS episodes) and uncontrolled CS (< 12 months since last uncontrolled episode). Patients were matched for age, sex, and origin and grade of tumour. When no matching patients were available, data from deceased patients were used. Information on healthcare resource use came from review of medical records, patient history and physician reports. Working capacity was assessed using the Work Productivity and Activity Impairment General Health questionnaire. Results Twenty-six university hospitals in Spain participated, between July 2017 and April 2018. 137 patients were enrolled; 104 were analysed (2 groups of 52). Patients with uncontrolled CS had 10 times more emergency department (ED) visits (mean 1.0 vs 0.10 visits; P = 0.0167), were more likely to have a hospital admission (40.4% vs 19.2%; P = 0.0116) and had longer hospital stays (mean 7.87 vs 2.10 days; P = 0.0178) than those with controlled CS. This corresponded to higher annual hospitalisation costs (mean €5511.59 vs €1457.22; P = 0.028) and ED costs (€161.25 vs €14.85; P = 0.0236). The mean annual total healthcare costs were 60.0% higher in patients with uncontrolled than controlled CS (P = NS). Conclusion This study quantifies higher health resource use, and higher hospitalisation and ED costs in patients with uncontrolled CS. Better control of CS may result 3in lower medical costs.

Carcinoid syndrome and neuroendocrine tumours

Medicine ◽  
2013 ◽  
Vol 41 (10) ◽  
pp. 566-569 ◽  
Author(s):  
Channa N. Jayasena ◽  
Waljit S. Dhillo
Keyword(s):  
Carcinoid Syndrome ◽  
Neuroendocrine Tumours

scholarly journals Primary neuroendocrine tumour of the left ventricle

2019 ◽  
Author(s):  
Michael P Rogers ◽  
Sarah Thomas ◽  
Leelakrishna Nallamshetty ◽  
Robert Hooker
Keyword(s):  
Gastrointestinal Tract ◽  
Left Ventricle ◽  
Carcinoid Syndrome ◽  
Neuroendocrine Tumours ◽  
Neuroendocrine Tumour ◽  
Left Ventricular ◽  
Unique Case ◽  
Asymptomatic Woman

Abstract Neuroendocrine tumours are rare neoplasms typically arising in the gastrointestinal tract that may result in carcinoid syndrome and/or acquired valvular dysfunction. Herein, we present a unique case of a 68-year-old asymptomatic woman with a primary left ventricular neuroendocrine tumour.

scholarly journals A guide to midgut neuroendocrine tumours (NETs) and carcinoid syndrome

2014 ◽  
Vol 6 (4) ◽  
pp. 264-269 ◽  
Author(s):  
Vincent T F Cheung ◽  
Mohid S Khan
Keyword(s):  
Carcinoid Syndrome ◽  
Neuroendocrine Tumours

scholarly journals Carcinoid syndrome in a child presenting with pancreatic somatotropinoma

2011 ◽  
Vol 57 (5) ◽  
pp. 46-51
Author(s):  
M A Kareva ◽  
E M Orlova ◽  
N S Kuznetsov ◽  
L E Kats ◽  
L E Gurevich ◽  
...  
Keyword(s):  
Carcinoid Syndrome ◽  
Neuroendocrine Tumours ◽  
Primary Tumour ◽  
Somatostatin Analogs ◽  
Negative Results ◽  
Vasoactive Substances ◽  
First Case ◽  
Enhanced Secretion ◽  
Metastatic Process ◽  
Immunohistochemical Studies

Carcinoid syndrome develops as a sequel of enhanced secretion of vasoactive substances from neuroendocrine tumours (NET). Somatostatinoma is an extremely rare variant of NET that manifests itself in cholelithiasis, steatorea, and diabetes mellitus. Somatostatinoma is usually diagnosed in adult subjects. Carcinoid syndrome is not a typical consequence of somatostatinoma. We present the first case report of somatostatinoma that was diagnosed in a child having carcinoid syndrome. The diagnosis was made difficult by the negative results of the search for biochemical markers of carcinoid syndrome and the small size of the primary tumour that could not be visualized by computed tomography. The immunohistochemical studies demonstrated secretion of somatostatin and calcitonin. The treatment of the child with somatostatin analogs proved inefficient which can be accounted for by the late diagnosis of the disease and the extensive metastatic process.

Sign in / Sign up

Export Citation Format

Share Document